Courts cite teen brain science to soften sentences; experts warn generalized neuroscience overreaches and adult responsibility stabilizes by 18 to 20.
|Articles|August 4, 2022
How Can This Medication Help?
Author(s)Rif S. El-Mallakh, MD
What is the first thing you share with your patient when you are about to prescribe a new medication?
Advertisement
In this episode of The Big Q, Rif El-Mallakh, MD, shares his approach to introducing patients to new medications, from explaining the medication’s mechanism of action to telling patients how the medication can help alleviate their most problematic symptoms.
Dr El-Mallakh is the director of the Mood Disorders Research Program at the University of Louisville School of Medicine in Louisville, Kentucky.
Advertisement
Related to this article
Can hormones flag suicide risk in schizophrenia? Review links cortisol, thyroid and testosterone shifts—and clozapine/lithium pathways—to risk.
How VA clinicians treat veterans’ PTSD while managing suicide risk, using shared decisions, safety planning, and phase-based trauma therapies.
RADIANT phase 2 shows once-daily remlifanserin eases Alzheimer’s psychosis symptoms with placebo-like safety, advancing pivotal trials.
Discover how integrated psychotherapy—CBTp, family support, and relapse plans—boosts schizophrenia recovery alongside antipsychotics.
FDA grants Breakthrough Device status to NET Recovery’s tACS wearable, aiming to curb cocaine and meth use and close a major treatment gap.
Learn how IPV shapes mental health from pregnancy to adulthood, and how clinicians assess risk, plan safety, and treat victims and perpetrators.
Early trial shows investigational orexin-2 agonist ALKS 7290 improves adult ADHD symptoms in 14 days, with tolerable safety, paving way for phase 2.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Adolescent Brain and Schizophrenia: What Research Reveals About Pruning, Dopamine, and Myelin
2
Exploring a Misuse of Neuroscience: How Biology Has Been Used to Remove Responsibility in Youth
3
Searching for a New TMS Target in Schizophrenia, With Andrew Pines, MD
4
Using Psychotherapy for the Prevention of Relapse in Schizophrenia
5